RESUMEN
COVID-19 and our armamentarium of strategies to combat it have evolved dramatically since the virus first emerged in late 2019. Vaccination remains the primary strategy to prevent severe illness, although the protective effect can vary in patients with hematologic malignancy. Strategies such as additional vaccine doses and now bivalent boosters can contribute to increased immune response, especially in the face of evolving viral variants. Because of these new variants, no approved monoclonal antibodies are available for pre-exposure or postexposure prophylaxis. Patients with symptomatic, mild-to-moderate COVID-19 and risk features for developing severe COVID-19, who present within 5-7 days of symptom onset, should be offered outpatient therapy with nirmatrelvir/ritonavir (NR) or in some cases with intravenous (IV) remdesivir. NR interacts with many blood cancer treatments, and reviewing drug interactions is essential. Patients with severe COVID-19 should be managed with IV remdesivir, tocilizumab (or an alternate interleukin-6 receptor blocker), or baricitinib, as indicated based on the severity of illness. Dexamethasone can be considered on an individual basis, weighing oxygen requirements and patients' underlying disease and their perceived ability to clear infection. Finally, as CD19-targeted and B-cell maturation (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies become more heavily used for relapsed/refractory hematologic malignancies, viral infections including COVID-19 are increasingly recognized as common complications, but data on risk factors and prophylaxis in this patient population are scarce. We summarize the available evidence regarding viral infections after CAR T-cell therapy.
Asunto(s)
COVID-19 , Neoplasias Hematológicas , Virosis , Humanos , Recurrencia Local de Neoplasia , Virosis/etiología , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/epidemiología , Neoplasias Hematológicas/terapia , Inmunoterapia Adoptiva/efectos adversosRESUMEN
Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.
Asunto(s)
Enfermedades Transmisibles/terapia , Neoplasias/complicaciones , Neoplasias/terapia , HumanosRESUMEN
Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.
Asunto(s)
Infecciones Bacterianas/prevención & control , Huésped Inmunocomprometido , Micosis/prevención & control , Neoplasias/complicaciones , Virosis/prevención & control , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Antivirales/uso terapéutico , Infecciones Bacterianas/etiología , Infecciones Bacterianas/inmunología , Infecciones Bacterianas/terapia , Trasplante de Células Madre Hematopoyéticas , Humanos , Micosis/etiología , Micosis/inmunología , Micosis/terapia , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Neutropenia/inducido químicamente , Neutropenia/complicaciones , Factores de Riesgo , Virosis/etiología , Virosis/inmunología , Virosis/terapiaAsunto(s)
Enfermedades Transmisibles/epidemiología , Huésped Inmunocomprometido , Neoplasias/complicaciones , Prevención Primaria , Corticoesteroides/administración & dosificación , Profilaxis Antibiótica , Antifúngicos/uso terapéutico , Enfermedades Transmisibles/etiología , Enfermedades Transmisibles/inmunología , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/prevención & control , Infecciones por Citomegalovirus/prevención & control , Humanos , Inmunidad Celular , Micosis/epidemiología , Micosis/prevención & control , Neoplasias/inmunología , Neutropenia/epidemiología , Enfermedades Nasales/epidemiología , Enfermedades Nasales/prevención & control , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/prevención & control , Medición de Riesgo , Infecciones de los Tejidos Blandos/epidemiología , Infecciones de los Tejidos Blandos/prevención & control , Vacunas Virales/administración & dosificación , Virosis/epidemiología , Virosis/prevención & controlRESUMEN
Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.